{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-085773","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.711203+00:00","generated_at":"2026-05-23T10:59:07.982968+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"confidence":"high","headline":"Tempest Therapeutics cuts 21 of 26 full-time staff, initiates strategic review","bullets":["Workforce reduced by 21 of 26 full-time employees, effective April 30, 2025.","Estimated $1.5M in cash severance and benefit costs, mostly in Q2 2025.","Key affected employees to transition to consulting agreements.","Company initiated process to explore strategic alternatives to extend capital resources."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-085773","json":"https://secwatch.observer/filing/0001193125-25-085773.json","markdown":"https://secwatch.observer/filing/0001193125-25-085773.md","text":"https://secwatch.observer/filing/0001193125-25-085773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525085773/0001193125-25-085773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525085773/d792758d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T10:59:07.982968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}